How many drugs treat Malignant melanoma?

Drug Landscape tracks 8 marketed treatments for Malignant melanoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/malignant-melanoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Malignant melanoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Malignant melanoma (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant melanoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Imlygic	TALIMOGENE LAHERPAREPVEC	Amgen			2015-01-01
Intron A	INTERFERON ALFA-2B	Merck & Co.	Interferon alpha		1986-01-01
Siklos	Siklos	Theravia		Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Xromi	Xromi	Nova Laboratories Limited		Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Imlygic	Imlygic	Johns Hopkins University
Hydroxycarbamide	Hydroxycarbamide	University of Birmingham		Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Hydroxycarbamid	Hydroxycarbamid	Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts		Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Vindesin	Vindesin	The Lymphoma Academic Research Organisation		Cytochrome P450 3A4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Malignant melanoma
Amgen · 1 drug in Malignant melanoma
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · 1 drug in Malignant melanoma
Johns Hopkins University · 1 drug in Malignant melanoma
Merck & Co. · 1 drug in Malignant melanoma
Nova Laboratories Limited · 1 drug in Malignant melanoma
The Lymphoma Academic Research Organisation · 1 drug in Malignant melanoma
Theravia · 1 drug in Malignant melanoma
University of Birmingham · 1 drug in Malignant melanoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant melanoma:

Cite this brief

Drug Landscape (2026). Malignant melanoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-melanoma. Accessed 2026-06-10.

Malignant melanoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing